Drug Database
BL

blood substitute (Volplex / Volplex)

✓ Approved

Sinclair · 细胞治疗 · 细胞治疗

什么是 blood substitute?

blood substitute 是一种细胞治疗,由Sinclair研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Volplex, Volplex
公司Sinclair
药物类别细胞治疗
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

blood substitute 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresAdjuvant therapy✓ Approved

相关研究文献

PubMedAJE advances : research in epidemiology2026-11-19

Development and validation of a 3-item Transportation Security Index for social risk screening assessments and research into the many pathways through which transportation impacts health.

Murphy Alexandra K AK, Griffin Jamie J, Gould-Werth Alix A

Clinicians and researchers studying transportation as a social determinant of health need measurement tools that screen for people with transportation problems and reveal the pathways through which transportation impacts health. Existing versions of the Transportation Security Index (TSI), a validated measure of transportation insecurity, are lengthy, making their use in research and clinical settings difficult. In this paper, we identify and validate an abbreviated 3-item TSI. We derive the TSI-3 from its 6-item counterpart (TSI-6) by analyzing 2022 survey data representative of the US population aged 25 years and older and content expert feedback. To validate the TSI-3, we embedded a split-ballot experiment in a 2024 survey with a similar sampling frame. We compared the TSI-3 and TSI-6's psychometric properties, ability to distinguish between transportation secure and insecure people, prevalence estimates, and associations with self-rated health and major depression. Results demonstrate that the TSI-3 is an effective substitute for the TSI-6 and is faster to administer by 56%. However, whereas the TSI-6 identifies 3 categories of transportation insecurity, the TSI-3 identifies 2. For those seeking a dichotomous measure of transportation insecurity for social risk screening and research purposes, the TSI-3 is an efficient and cost-effective measure.

PMID 43053811
阅读全文 →
PubMedJournal of cell science2026-11-19

AlphaFold-Multimer reveals diverse cyclin-CDK substrate docking interactions.

Willich Sarah S, Kapadia Nitin N, Nurse Paul P

Cyclin-dependent kinases (CDKs) control eukaryotic cell-cycle progression by phosphorylating specific substrates with substrate recognition often involving cyclin-specific docking interactions. However, in minimal cell cycle control systems driven by a single cyclin-CDK complex, how docking interactions contribute to the differential timing of substrate phosphorylation remains unclear. Here, we used AlphaFold-Multimer to systematically predict interactions between the fission yeast mitotic cyclin-CDK fusion Cdc13-L-Cdc2 and its known in vivo CDK substrates. We found that many substrates are predicted to interact with the cyclin hydrophobic patch, and have identified a previously uncharacterised docking motif, [FVIPWGLAM](x)xER[LMV] (ERL motif), with features consistent with an atypical RxL motif. We show that ERL motifs can functionally substitute for canonical RxL motifs to promote phosphorylation of a model CDK substrate by Cdc13-Cdc2, while the S-phase cyclin-CDK Cig2-Cdc2 was found to preferentially phosphorylate substrates containing canonical RxL motifs. Interestingly, Cdc13-L-Cdc2 was not predicted to bind DNA replication substrates preferentially over mitotic substrates, suggesting that other mechanisms underlie the temporal ordering of CDK substrate phosphorylation. These results reveal that cyclin-CDK-substrate interactions are more diverse than previously thought.

PMID 43053692
阅读全文 →
PubMedBMC endocrine disorders2026-11-19

Reduced circulating osteopontin levels are associated with elevated blood pressure and vascular endothelial-related alterations in children with obesity.

Guo Shuang S, Xu Dong D, Liu Yuesheng Y, Feng Wenxin W et al.

Childhood obesity is associated with metabolic abnormalities and elevated blood pressure, increasing the risk of early cardiovascular complications. Osteopontin (OPN), a multifunctional protein involved in inflammation and vascular homeostasis, has been implicated in cardiometabolic disorders. However, its association with blood pressure alterations in children with obesity remains unclear. This study aimed to investigate the associations of serum OPN levels with metabolic parameters, vascular endothelial-related markers, and elevated blood pressure in children with obesity. A total of 106 children were enrolled, including 61 children with obesity and 45 non-obese controls. Anthropometric parameters, metabolic profiles, blood pressure, circulating OPN and adiponectin (ADPN) levels, as well as vascular endothelial-related markers were assessed. Correlation analyses were performed to evaluate associations between OPN and clinical variables. Multivariable linear regression analysis was conducted to evaluate the association between OPN and systolic blood pressure (SBP) in children with obesity. Receiver operating characteristic (ROC) curve analysis was performed to assess the performance of OPN-containing models for identifying elevated blood pressure. Children with obesity showed higher BMI, blood pressure, triglycerides, total cholesterol, and vascular cell adhesion molecule-1 (VCAM-1), whereas circulating OPN, adiponectin (ADPN), Wnt family member 5 A (WNT5A), and endothelial cell-specific molecule 1 (ESM1) levels were lower compared with controls (all p < 0.05). In addition, OPN levels were inversely correlated with BMI (r = 0.704, p < 0.001), SBP (r = -0.557, p < 0.001), DBP (r = -0.279, p = 0.013), and VCAM-1 (r = -0.355, p = 0.001), but positively correlated with WNT5A and ESM1 (all p < 0.05). After adjustment for age, sex, and pubertal status, OPN was associated with lower SBP (β = -0.452, 95% CI: -4.30 to -0.74, p = 0.007). The addition of OPN to the basic clinical model improved its ability to identify elevated blood pressure, with the AUC increasing from 0.756 to 0.806. Circulating OPN levels are inversely associated with obesity, blood pressure, and are correlated with vascular endothelial-related markers in children. The findings suggest that serum OPN may serve as a potential biomarker of cardiometabolic risk in children with obesity.

PMID 43052972
阅读全文 →
PubMedBiomarkers in medicine2026-11-19

Routine blood count model to distinguish thalassemia trait without iron deficiency from iron deficiency anemia.

Cai Lixiu L, Li Ya Y, Zhang Jiaosha J, Zhang Jin J et al.

To develop a routine blood count model for distinguishing thalassemia trait/carrier status without iron deficiency from iron deficiency anemia (IDA) in individuals with microcytic hypochromic features. This single-center retrospective study assessed 156 participants aged 5-30 years. The primary model comparison included 98 participants with thalassemia trait/carrier status without iron deficiency and 50 with IDA. Stepwise logistic regression was evaluated by discrimination, calibration, bootstrap validation, decision curve analysis, and sensitivity analysis. Red blood cell count, mean corpuscular volume, and red cell distribution width-coefficient of variation were retained. The apparent area under the receiver operating characteristic curve was 0.998 (95% confidence interval 0.994-1.000). At a probability threshold of 0.50, sensitivity was 98.0% and specificity was 96.0%. The bootstrap mean area under the curve was 0.997. The model showed strong internal performance as an auxiliary tool for the studied groups. Independent external validation is required before wider clinical use.

PMID 43053738
阅读全文 →
PubMedLasers in medical science2026-11-19

Er: YAG laser for lip and perioral remodelling with emphasis on SMOOTH® mode: a systematic review of clinical evidence.

Giovannacci Ilaria I, Iaria Roberta R, Maffei Renzo R, Antonelli Rita R et al.

This review aimed to assess the current evidence on the use of Er: YAG laser for non-injective lip and perioral aesthetic remodelling, with emphasis on SMOOTH® mode and to determine whether the reported treatment outcomes reflect true lip-volume augmentation or perceived fullness resulting from tissue remodelling. A systematic literature search was conducted in MEDLINE/PubMed, Web of Science, Scopus, and the Cochrane Library, with no date restrictions. Studies were eligible if they reported clinical outcomes after 2940-nm Er:YAG laser treatment relevant to the lips, labial mucosa, perioral region, nasolabial folds, or anatomically related areas. Risk of bias was assessed using RoB 2 for randomized or split-face randomized studies and ROBINS-I for non-randomized prospective studies. Five studies involving 80 participants across mixed facial cohorts were included; only a subset received labial or isolated perioral treatment. Two studies were classified as Level 2b evidence and two as Level 4 evidence. No study measured objective lip volume, vermilion height, lip projection, Cupid's bow definition or validated lip-specific fullness outcomes. One study measured upper-lip morphology with three-dimensional stereophotogrammetry, reporting shortening of the philtral length and a decreased nasolabial angle, but did not quantify lip volume. Evidence was more consistent for perioral rejuvenation, nasolabial fold remodelling, rhytid reduction, dermal thickening, skin texture improvement, and collagen remodelling. Reported adverse events were generally transient, although post-inflammatory hyperpigmentation and labial herpes simplex reactivation were clinically relevant safety considerations. Current evidence supports Er:YAG laser as a biologically plausible and clinically promising modality for perioral rejuvenation and tissue-quality improvement. However the five eligible studies were heterogeneous, drew on mixed facial cohorts, and only one of them assessed the labial unit directly, measuring upper-lip morphology rather than volumeThe evidence is therefore insufficient to demonstrate true objective lip-volume augmentation - though this does not mean such augmentation does not occur. Er:YAG laser should be described as a non-injective remodelling approach that may enhance perceived fullness through tissue remodelling, rather than as a proven volumetric substitute for injectable fillers, and its effects should not be extrapolated between modalities.

PMID 43052576
阅读全文 →
PubMedBMC medicine2026-11-19

Effect of remote ischemic conditioning on cerebral blood flow regulation in patients with ischemic stroke: a randomized, controlled trial.

Wang Si-Ji SJ, Yin Wen-Jing WJ, Zhang Fu-Liang FL, Qu Yang Y et al.

Acute ischemic stroke (AIS) is a major contributor to long-term disability despite current therapies. Although remote ischemic conditioning (RIC) has potential benefits in patients with AIS, its underlying mechanisms remain poorly understood. We aimed to explore the effects of RIC on the regulation of cerebral blood flow (CBF) among patients with AIS. This was a randomized controlled trial with participant-and-blinded endpoints that included 120 patients with AIS from June 2023 to May 2024. RIC/sham RIC treatment was performed at a pressure of 200 mmHg or 60 mmHg twice a day for seven consecutive days. The primary efficacy outcome was the difference in CBF regulation 7 days after randomization between the two groups. Patients were followed up for 90 days after randomization to assess modified Rankin Scale (mRS) scores. One hundred and twenty (120) patients with AIS were included in the intention-to-treat population (60 in each group). The results showed that the phase difference, which is a key parameter of CBF regulation, in the RIC group was significantly higher than that in the sham RIC group [affected side: RIC group: 36.84° (interquartile range [IQR], 21.49° to 51.36°), sham RIC group: 28.57° (17.17°, 38.52°), adjusted β coefficient = 11.336, 95% confidence interval (CI) = 4.523-18.149, P = 0.001; unaffected side: RIC group: 35.13° (20.77°, 56.51°), sham RIC group: 30.37° (15.65°, 40.11°), adjusted β coefficient = 11.780, 95% CI = 4.260-19.300, P = 0.002]. Additionally, there were no statistically significant differences in the secondary outcomes including blood pressure, heart rate, cerebral blood flow velocity in the middle cerebral artery, and 90-day mRS scores between the two groups (P > 0.05). RIC treatment did not increase adverse events during hospitalization. RIC can significantly improve CBF regulation in patients with AIS, which may be an intermediate mechanism by which it benefits this patient population. Clinical Trial Number: NCT05915832, Clinical Trial Registry: ClinicalTrials.gov, Registration Date: 2023-06-23.

PMID 43053040
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多blood substitute